Rhythm Pharmaceuticals (RYTM) Income towards Parent Company (2020 - 2025)
Historic Income towards Parent Company for Rhythm Pharmaceuticals (RYTM) over the last 6 years, with Q3 2025 value amounting to -$52.9 million.
- Rhythm Pharmaceuticals' Income towards Parent Company fell 2122.55% to -$52.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$192.3 million, marking a year-over-year increase of 2572.22%. This contributed to the annual value of -$260.6 million for FY2024, which is 4111.16% down from last year.
- Per Rhythm Pharmaceuticals' latest filing, its Income towards Parent Company stood at -$52.9 million for Q3 2025, which was down 2122.55% from -$46.6 million recorded in Q2 2025.
- In the past 5 years, Rhythm Pharmaceuticals' Income towards Parent Company ranged from a high of $43.8 million in Q1 2021 and a low of -$141.4 million during Q1 2024
- Moreover, its 5-year median value for Income towards Parent Company was -$44.2 million (2023), whereas its average is -$44.9 million.
- Per our database at Business Quant, Rhythm Pharmaceuticals' Income towards Parent Company surged by 22805.88% in 2021 and then crashed by 22007.09% in 2022.
- Over the past 5 years, Rhythm Pharmaceuticals' Income towards Parent Company (Quarter) stood at -$50.9 million in 2021, then rose by 16.44% to -$42.5 million in 2022, then increased by 2.02% to -$41.6 million in 2023, then fell by 3.98% to -$43.3 million in 2024, then decreased by 22.2% to -$52.9 million in 2025.
- Its last three reported values are -$52.9 million in Q3 2025, -$46.6 million for Q2 2025, and -$49.5 million during Q1 2025.